Scribe Therapeutics Inc. financial statements
Scribe Therapeutics Inc.'s income statement, balance sheet and cash flow, annual and quarterly, each figure dated and linked to the filing it was read from.
FY2025
| Revenue | USD 51.17M | EODHD |
| Net income | −USD 21.81M | EODHD |
| Cash and equivalents | USD 12.8M | EODHD |
| Total debt | USD 41.43M | EODHD |
Scribe Therapeutics Inc. financials on 6ix · Scribe Therapeutics Inc. on 6ix